The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals
暂无分享,去创建一个
P. Reiss | J. Beijnen | F. Wit | N. Foudraine | S. Danner | J. Lange | J. Mulder | R. Hoetelmans | J. Lange | P. Meenhorst | R. V. van Heeswijk | A. Veldkamp | M. Kwakkelstein | Richard M. W. Hoetelmans | Pieter L. Meenhorst | Rolf P. G. van Heeswijk | Norbert A. Foudraine | Marthin O. Kwakkelstein
[1] D Johnson,et al. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. , 1999, AIDS.
[2] A. Telenti,et al. Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. , 1999, Journal of acquired immune deficiency syndromes.
[3] Julio S. G. Montaner,et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long‐term response to therapy , 1998, AIDS.
[4] J. Beijnen,et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. , 1998, Journal of chromatography. B, Biomedical sciences and applications.
[5] V. M. Shadle,et al. Self-reported antiretroviral therapy in injection drug users. , 1998, JAMA.
[6] B. Bruguerolle,et al. Chronopharmacokinetics , 1998, Clinical pharmacokinetics.
[7] W. Dolmans,et al. Low Plasma Concentrations of Indinavir are Related to Virological Treatment Failure in HIV-1-Infected Patients on Indinavir-Containing Triple Therapy , 1998, Antiviral therapy.
[8] J. Montaner,et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. , 1998, JAMA.
[9] P. Krogstad,et al. Combination treatment with zidovudine, didanosine, and nevirapine in infants with human immunodeficiency virus type 1 infection. , 1997, The New England journal of medicine.
[10] M. Moroni,et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. , 1997, The Journal of infectious diseases.
[11] T. Greenough,et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. , 1995, The Journal of infectious diseases.
[12] J L Sullivan,et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans , 1993, Antimicrobial Agents and Chemotherapy.
[13] R S Woodward,et al. The effect of prescribed daily dose frequency on patient medication compliance. , 1990, Archives of internal medicine.
[14] J. Montaner,et al. Drug Evaluations Anti-infectives: Nevirapine: A review of its development, pharmacological profile and potential for clinical use , 1996 .